Literature DB >> 21724466

Bile acids and colon cancer: Solving the puzzle with nuclear receptors.

Chiara Degirolamo1, Salvatore Modica, Giuseppe Palasciano, Antonio Moschetta.   

Abstract

Colorectal cancer is the third most common malignancy worldwide and is often linked to obesity, a sedentary lifestyle, carbohydrate- and fat-rich diets and elevated fecal excretion of secondary bile acids. Accumulation of toxic bile acids triggers oxidative damage, mitochondrial dysfunction and tumor progression. Nuclear receptors are transcription factors crucially involved in the regulation of bile acid metabolism and detoxification, and their activation may confer protection from bile acid tumor-promoting activity. In this review, we explore the tangled relationships among bile acids, nuclear receptors and the intestinal epithelium, with particular emphasis on the role of the farnesoid X receptor in colorectal cancer prevention and on novel nuclear receptor-based approaches to expand the portfolio of chemotherapeutic agents.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724466     DOI: 10.1016/j.molmed.2011.05.010

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  59 in total

1.  Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.

Authors:  Zhongsheng Peng; Jiayan Chen; Cinthia B Drachenberg; Jean-Pierre Raufman; Guofeng Xie
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

2.  Microbial Metabolites as Molecular Mediators of Host-Microbe Symbiosis in Colorectal Cancer.

Authors:  N P Hyland; A Houston; J M Keane; S A Joyce; C G M Gahan
Journal:  Results Probl Cell Differ       Date:  2020

3.  Synthesis, Structure-Activity Relationship, and Mechanistic Investigation of Lithocholic Acid Amphiphiles for Colon Cancer Therapy.

Authors:  Manish Singh; Sandhya Bansal; Somanath Kundu; Priyanshu Bhargava; Ashima Singh; Rajender K Motiani; Radhey Shyam; Vedagopuram Sreekanth; Sagar Sengupta; Avinash Bajaj
Journal:  Medchemcomm       Date:  2014-10-15       Impact factor: 3.597

4.  Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin.

Authors:  Femke-Anouska Heinsen; Henrik Knecht; Sven C Neulinger; Ruth A Schmitz; Carolin Knecht; Tanja Kühbacher; Philip C Rosenstiel; Stefan Schreiber; Anette K Friedrichs; Stephan J Ott
Journal:  Gut Microbes       Date:  2015-07-04

Review 5.  Obesity and cancer: A mechanistic overview of metabolic changes in obesity that impact genetic instability.

Authors:  Pallavi Kompella; Karen M Vasquez
Journal:  Mol Carcinog       Date:  2019-06-05       Impact factor: 4.784

Review 6.  Dietary fibre in gastrointestinal health and disease.

Authors:  Samantha K Gill; Megan Rossi; Balazs Bajka; Kevin Whelan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-11-18       Impact factor: 46.802

Review 7.  Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases.

Authors:  Er-Teng Jia; Zhi-Yu Liu; Min Pan; Jia-Feng Lu; Qin-Yu Ge
Journal:  J Zhejiang Univ Sci B       Date:  2019 Oct.       Impact factor: 3.066

8.  Functional genomic analyses of the gut microbiota for CRC screening.

Authors:  Sergey R Konstantinov; Ernst J Kuipers; Maikel P Peppelenbosch
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 9.  Inflammation and colorectal cancer, when microbiota-host mutualism breaks.

Authors:  Marco Candela; Silvia Turroni; Elena Biagi; Franck Carbonero; Simone Rampelli; Carla Fiorentini; Patrizia Brigidi
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

10.  Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer.

Authors:  Suhasini Joshi; Eric Cruz; Satyanarayana Rachagani; Sushovan Guha; Randall E Brand; Moorthy P Ponnusamy; Sushil Kumar; Surinder K Batra
Journal:  Mol Oncol       Date:  2016-04-29       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.